Spero Therapeutics (SPRO)
(Delayed Data from NSDQ)
$1.37 USD
0.00 (0.00%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $1.36 -0.01 (-0.73%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.37 USD
0.00 (0.00%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $1.36 -0.01 (-0.73%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth B Momentum F VGM
Zacks News
Gilead's (GILD) Leukemia Study Progress Put on Clinical Hold
by Zacks Equity Research
Gilead (GILD) faces a setback as the FDA puts a partial clinical hold on enrolling new patients in studies evaluating magrolimab for treating AML in the United States.
Novartis (NVS) Plans to Spin-Off Sandoz in Early October
by Zacks Equity Research
Novartis (NVS) progresses with the proposed spin-off of its Sandoz arm (scheduled for early October) and invites shareholders for a meeting on the same.
Regeneron's (REGN) Application for Blood Cancer Drug Accepted
by Zacks Equity Research
Regeneron's (REGN) application seeking approval of odronextamab for patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma gets accepted for review in the EU.
Bristol Myers (BMY) Announces Positive Updated NSCLC Data
by Zacks Equity Research
Bristol Myers' (BMY) repotrectinib shows durable efficacy benefits in patients with locally advanced or metastatic ROS1-Positive non-small cell lung cancer.
Gilead (GILD), Tentarix To Develop Cancer, Inflammation Therapies
by Zacks Equity Research
Gilead (GILD) enters into a deal with Tentarix Biotherapeutics to discover and develop novel therapies for cancer and inflammation.
Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65%
by Zacks Equity Research
Due to a lack of funding needs, Alaunos (TCRT) decides to end its only clinical study. The company will instead focus on its hunTR TCR discovery platform and explore broad strategic alternatives.
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 20.69% and 23.46%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Pliant Therapeutics, Inc. (PLRX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Pliant Therapeutics, Inc. (PLRX) delivered earnings and revenue surprises of 4.11% and 77.46%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
CytomX Therapeutics (CTMX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 89.47% and 42.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Kymera Therapeutics, Inc. (KYMR) delivered earnings and revenue surprises of 4.29% and 18.39%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in TELA Bio, Inc. (TELA): Can Its 11.4% Jump Turn into More Strength?
by Zacks Equity Research
TELA Bio, Inc. (TELA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Bausch (BHC) Gains on Court Ruling for Xifaxan Against Norwich
by Zacks Equity Research
Bausch (BHC) obtains a positive ruling for one of its top drugs, Xifaxan, against Norwich from the U.S. District Court of Delaware. Stock up in response to the same.
Intercept (ICPT) Gains 26.2% YTD: What's in Store?
by Zacks Equity Research
Intercept (ICPT) has been having a good run in the year so far, but investors are wary ahead of the upcoming advisory meeting by the FDA's Gastrointestinal Drugs Advisory Committee to review its NDA seeking approval of OCA in steatohepatitis (NASH).
Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 28.57% and 3.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Exelixis (EXEL) Q1 Earnings Miss, Revenues Increase Y/Y
by Zacks Equity Research
Exelixis (EXEL) misses first quarter 2023 earnings and sales estimates, but product sales increase year over year.
bluebird (BLUE) Posts Q1 Earnings, Focuses on Zynteglo, Skysona
by Zacks Equity Research
bluebird bio (BLUE) delivers earnings of 21 cents per share in the first quarter, due to a one-time gain. Revenues increase year over year.
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -61% and 67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Perrigo (PRGO) Tops Q1 Earnings & Sales, Reiterates '23 View
by Zacks Equity Research
Perrigo (PRGO) reports encouraging first-quarter 2023 results. Management reaffirms the financial guidance for 2023. The company's current CEO announces plans to retire by the end of July.
Viatris (VTRS) Q1 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Viatris (VTRS) beats on Q1 earnings but misses sales. The company is now looking to reshape its business after selling its biosimilars portfolio.
Bausch Health's (BHC) Q1 Earnings & Sales Miss, Shares Down
by Zacks Equity Research
Bausch (BHC) declines as it misses on earnings and sales in the first quarter.
Karuna (KRTX) Reports Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Karuna Therapeutics (KRTX) reports encouraging first-quarter 2023 results. The company beats estimates for earnings and sales.
Agios (AGIO) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) reports encouraging first-quarter results, beating estimates for earnings and sales.
Moderna (MRNA) Q1 Earnings & Sales Top Estimates, Stock Up 2%
by Zacks Equity Research
Moderna (MRNA) beats expectations for both earnings and sales. The company posts higher-than-expected product sales from its COVID vaccine
FATE Incurs Narrower-Than-Expected Q1 Loss on Lower Expenses
by Zacks Equity Research
FATE reports lower-than-expected loss on higher collaboration revenues and lower operating expenses in first-quarter 2023.
Allogene's (ALLO) Q1 Loss Wider Than Expected, Sales Miss
by Zacks Equity Research
Allogene's (ALLO) first-quarter results miss both earnings and sales estimates.